Insider Selling: Artivion, Inc. (NYSE:AORT) SVP Sells 5,335 Shares of Stock

Artivion, Inc. (NYSE:AORT) SVP Jean F. Holloway sold 5,335 shares of the business’s stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $27.31, for a total transaction of $145,698.85. Following the transaction, the senior vice president now owns 149,799 shares in the company, valued at $4,091,010.69. This represents a 3.44 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Artivion Trading Down 0.1 %

NYSE:AORT opened at $25.34 on Friday. Artivion, Inc. has a one year low of $18.38 and a one year high of $32.33. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.88 and a quick ratio of 1.33. The company’s 50-day simple moving average is $29.58 and its 200 day simple moving average is $27.80. The firm has a market capitalization of $1.06 billion, a P/E ratio of -1,267.00 and a beta of 1.75.

Artivion (NYSE:AORT) last issued its earnings results on Monday, February 24th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.12 by ($0.51). The firm had revenue of $97.31 million during the quarter, compared to the consensus estimate of $100.82 million. Artivion had a positive return on equity of 5.15% and a negative net margin of 0.22%. As a group, analysts forecast that Artivion, Inc. will post 0.37 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts recently issued reports on AORT shares. Oppenheimer boosted their price target on shares of Artivion from $30.00 to $32.00 and gave the company an “outperform” rating in a research report on Friday, November 8th. Needham & Company LLC reduced their price target on shares of Artivion from $34.00 to $32.00 and set a “buy” rating on the stock in a research report on Tuesday. Stifel Nicolaus reduced their price target on shares of Artivion from $33.00 to $30.00 and set a “buy” rating on the stock in a research report on Tuesday. Finally, JMP Securities reissued a “market outperform” rating and set a $33.00 price objective on shares of Artivion in a research note on Tuesday, December 10th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $31.40.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in AORT. Creative Planning lifted its stake in shares of Artivion by 182.1% in the third quarter. Creative Planning now owns 28,635 shares of the company’s stock worth $762,000 after buying an additional 18,486 shares in the last quarter. RiverPark Advisors LLC lifted its stake in shares of Artivion by 151.6% in the third quarter. RiverPark Advisors LLC now owns 5,387 shares of the company’s stock worth $143,000 after buying an additional 3,246 shares in the last quarter. Quest Partners LLC lifted its stake in shares of Artivion by 2,481,700.0% in the third quarter. Quest Partners LLC now owns 24,818 shares of the company’s stock worth $661,000 after buying an additional 24,817 shares in the last quarter. Intech Investment Management LLC lifted its stake in shares of Artivion by 6.6% in the third quarter. Intech Investment Management LLC now owns 10,530 shares of the company’s stock worth $280,000 after buying an additional 653 shares in the last quarter. Finally, The Manufacturers Life Insurance Company lifted its stake in shares of Artivion by 28.1% in the third quarter. The Manufacturers Life Insurance Company now owns 19,596 shares of the company’s stock worth $522,000 after buying an additional 4,295 shares in the last quarter. Institutional investors own 86.37% of the company’s stock.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.